ANI Pharmaceuticals, Inc.
ANIP
$65.39
$0.440.68%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 131.65M | 131.83M | 116.55M | 106.79M | 94.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 131.65M | 131.83M | 116.55M | 106.79M | 94.23M |
| Cost of Revenue | 53.42M | 48.10M | 42.28M | 37.71M | 36.33M |
| Gross Profit | 78.23M | 83.73M | 74.26M | 69.08M | 57.91M |
| SG&A Expenses | 44.46M | 42.01M | 38.76M | 36.47M | 23.79M |
| Depreciation & Amortization | 15.19M | 15.21M | 14.69M | 14.70M | 14.48M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.94M | 116.44M | 103.11M | 94.80M | 79.82M |
| Operating Income | 8.71M | 15.39M | 13.44M | 11.99M | 14.41M |
| Income Before Tax | 947.00K | 11.51M | 5.25M | 2.17M | -5.73M |
| Income Tax Expenses | -208.00K | 1.57M | -996.00K | 726.00K | -1.49M |
| Earnings from Continuing Operations | 1.16M | 9.94M | 6.25M | 1.44M | -4.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.16M | 9.94M | 6.25M | 1.44M | -4.24M |
| EBIT | 8.71M | 15.39M | 13.44M | 11.99M | 14.41M |
| EBITDA | 23.91M | 30.60M | 28.13M | 26.69M | 29.98M |
| EPS Basic | 0.04 | 0.46 | 0.30 | 0.06 | -0.28 |
| Normalized Basic EPS | 0.20 | 0.30 | 0.22 | 0.16 | 0.35 |
| EPS Diluted | 0.04 | 0.45 | 0.29 | 0.06 | -0.29 |
| Normalized Diluted EPS | 0.19 | 0.29 | 0.22 | 0.16 | 0.35 |
| Average Basic Shares Outstanding | 19.00M | 18.88M | 17.69M | 16.39M | 16.33M |
| Average Diluted Shares Outstanding | 19.22M | 19.13M | 17.86M | 16.53M | 16.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 35.15% | 4.08% | 6.52% | 28.21% | -9.59% |
